Iowa Senator Chuck Grassley says there are "serious probems" with the settlement announced between the US Justice Department and Epipen maker Mylan over the misclassification of the drug. Grassley says it looks like the settlement amount shortchanges the taxpayers. He says the government's own watchdog said the taxpayers may have overpaid for Epipen by over $1.2 billion under the Medicaid drug rebate program. The Justice Department arrived at about $465 million in overpayments for a similar time period. Grassley called the settlement a disappointment and said the agencies that are supposed to look out for taxpayers should not be pulling their punches.